Diagnostic value of high sensitivity C-reactive protein in differentiating unstable angina from myocardial infarction
DOI:
https://doi.org/10.22122/cdj.v1i1.27Keywords:
Myocardial Infarction, Acute Coronary Syndrome, Unstable Angina, DiagnosisAbstract
BACKGROUND: Differentiating between unstable angina and myocardial infarction (MI) is clinically important as they require different treatments. High sensitivity C-reactive protein (hs-CRP) has recently been recognized as prognostic factor in acute coronary syndrome. Since this biomarker may indicate the prognosis of heart disease, identifying its diagnostic value will be clinically important. This study investigated the diagnostic value of the level of hs-CRP in differentiating MI from unstable angina.
METHODS: Blood samples were obtained from all patients with suspected MI or unstable angina at the time of referral. The patients were put in one of the two groups based on final diagnosis. The exclusion criteria were infectious diseases, immune system diseases, history of a recent surgery or trauma, kidney failure, liver failure, cancers, and use of anti-inflammatory drugs. Data was entered in SPSS and analyzed by independent t-test, Mann-Whitney U and chi-square or Fisher’s exact test. ROC curve was used to determine hs-CRP cut-off point. The sensitivity and specificity were calculated at the cut-off point.
RESULTS: Overall, 60 patients (30 patients with MI and 30 patients with unstable angina) were studied. Hs-CRP level was 3.68 ± 0.86 mg/l in patients with MI and 2.35 ± 1.30 mg/l in patients with unstable angina
(P < 0.001). The best cut-off point for differentiating unstable angina from MI was hs-CRP levels equal to or greater than 3.27 mg/l. At this cutoff point, the sensitivity and specificity were both 77%.
CONCLUSION: Patients with MI had higher levels of hs-CRP than subjects with unstable angina. Hs-CRP levels equal to or higher than 3.27 mg/l are more likely to be associated with MI. It is recommended to test this biomarker in all patients with acute coronary syndrome.
References
Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47(3): 418-25.
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107(3): 363-9.
Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol 2008; 28(7): 1385-91.
Thakur S, Gupta S, Parchwani H, Shah V, Yadav V. Hs-CRP - A Potential Marker for Coronary Heart Disease. Indian Journal of Fundamental and Applied Life Sciences 2011; 1(1): 1-4.
Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169(2): 203-14.
Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006; 113(1): 38-43.
Zairis MN, Adamopoulou EN, Manousakis SJ, Lyras AG, Bibis GP, Ampartzidou OS, et al. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 2007; 194(2): 397-402.
Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol 2009; 53(3): 317-33.
Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115(12): 1528-36.
Kazerani H, Rai AR. Correlation between serum high sensitivity CRP level and in hospital cardiac events in the patients with unstable angina. Sci J Hamdan Univ Med Sci 2007; 14(3): 5-9. [In Persian].
Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917): 868-74.
Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47(3): 444-50.
Schaan BD, Pellanda LC, Maciel PT, Duarte ER, Portal VL. C-reactive protein in acute coronary syndrome: association with 3-year outcomes. Braz J Med Biol Res 2009; 42(12): 1236-41.
Zairis MN, Manousakis SJ, Stefanidis AS, Papadaki OA, Andrikopoulos GK, Olympios CD, et al. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J 2002; 144(5): 782-9.
Yip HK, Hang CL, Fang CY, Hsieh YK, Yang CH, Hung WC, et al. Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest 2005; 127(3): 803-8.
Diercks DB, Kirk JD, Naser S, Turnipseed S, Amsterdam EA. Value of high-sensitivity C-reactive protein in low risk chest pain observation unit patients. Int J Emerg Med 2011; 4: 37.
Tanaka A, Shimada K, Sano T, Namba M, Sakamoto T, Nishida Y, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol 2005; 45(10): 1594-9.
Yip HK, Wu CJ, Chang HW, Yang CH, Yeh KH, Chua S, et al. Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest 2004; 126(5): 1417-22.
Amanvermez R, Acar E, Gunay M, Baydin A, Yardan T, Bek Y. Hsp 70, hsCRP and oxidative stress in patients with acute coronary syndromes. Bosn J Basic Med Sci 2012; 12(2): 102-7.
Gharakhani M, Moradi M. A survey on the predictive value of high-sensitive c-reactive protein in patients with unstable angina. Sci J Hamdan Univ Med Sci 2012; 19(2): 23-7. [In Persian].
